[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-acute":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,45,81,122,152,188,228,263,291,322,344,366,390],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100649023","phase-2-nebulized-ketamine-for-severe-asthma-attacks-in-children-100649023",false,"NCT07728851","Nebulized Ketamine for Severe Asthma Attacks in Children","Effectiveness and Safety of Nebulized Ketamine in Severe Pediatric Asthma: a Phase-2, Double-blind, Randomized, Placebo-controlled Pilot Trial","Inclusion Criteria:\n\n* Children aged 1 to 13 years.\n* Diagnosis of severe asthma exacerbation (PRAM score 8-12)\n* Prior treatment with standard first-line management (beta-2 agonist, corticosteroid, magnesium sulfate)\n\nExclusion Criteria:\n\n* Known allergy or adverse reaction to ketamine\n* Significant hemodynamic instability\n* Systemic hypertension \\>95th percentile for age\n* Cardiac arrhythmias\n* Congestive heart failure\n* Obstructive sleep apnea with AHI \\>5","ALL","1 Year","13 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a double-blinded, randomised, placebo-controlled trial enrolling 60 children aged 1 to 13 years with severe asthma exacerbation. All participants will receive standard therapy. Children not responding to standard therapy will be randomised to intervention arms. Randomization will occur in a 1:1 ratio using a computer-generated Excel sequence with permuted blocks of four, stratified by age (1-5 and 6-13 years). Patients will receive either nebulized ketamine (1 mg\u002Fkg every 6 hours for 24 hours) or 0.9% normal saline placebo. Randomization codes will be maintained by the hospital pharmacy, which will prepare identical numbered packs. During working hours, the pharmacist will dispense the allocated medication; at nights and weekends, pre-prepared packs will be stored securely in the PHDU\u002FPICU under the supervision of the nursing in-charge. Blinding will be maintained for patients, clinicians, and outcome assessors. PRAM scores will be recorded at baseline and at 20, 60, 90, and 120 minutes post-dose. The primary outcome is pediatric respiratory assessment measure (PRAM) score change. Secondary outcomes include need for NIV or intubation and HDU\u002FPICU length of stay.",[27,28],"Asthma Acute","Exacerbation of Allergic Asthma",[30,31],"Asthma","Ketamine","NOT_YET_RECRUITING","2026-07-23",{"date":35,"type":36},"2026-07-27","ACTUAL",{"date":38,"type":21},"2027-01-01",{"date":40,"type":21},"2029-12-31",{"name":42,"class":43},"Sultan Qaboos University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":44},"100647067","phase-2-rademikibart-iv-for-acute-asthma-and-copd-exacerbation-100647067","NCT07705737","Rademikibart IV for Acute Asthma and COPD Exacerbation","A Phase 2, Open-Label, Single-Arm Trial to Evaluate IV Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Asthma and or COPD With Type 2 Inflammation","Inclusion Criteria - Asthma cohort\n\n* Body weight of ≥40 kg and BMI ≤45 kg\u002Fm2 at SV1a.\n* Physician-diagnosed asthma\n* Currently receiving treatment with low, medium, to high dose ICS in combination with at least 1 additional asthma controller medication.\n* Must have experienced at least 1 asthma exacerbation requiring the use of systemic corticosteroids.\n* Participants in a stable condition, must have a historical peripheral blood eosinophil count of ≥250 cells\u002FμL and\u002For FeNO ≥ 25 ppb.\n* Current acute asthma exacerbation requiring an urgent healthcare visit for treatment.\n* Peripheral blood eosinophil count of ≥300 cells\u002FµL as part of the assessment of an index acute asthma exacerbation.\n* Requires systemic corticosteroid as SoC in the urgent healthcare setting to treat the current acute asthma exacerbation.\n* FEV1 ≥30% predicted.\n\nExclusion Criteria - Asthma cohort\n\n* Regular use of immunosuppressive medication.\n* Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension.\n* Current or former smoker, with a smoking history of ≥5 pack-years if \\\u003C30 years old or ≥10 pack-years if ≥30 years old\n* COPD and other clinically significant pulmonary disease other than asthma.\n* Known or suspected history of immunosuppression.\n* History of known immunodeficiency disorder or hepatitis B or C.\n* History of alcohol abuse and\u002For drug abuse.\n* Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix or other malignancies treated with apparent success with curative therapy.\n* Female participant who is pregnant, lactating or breast-feeding.\n* Recent receipt of any marketed nonbiologic drug that modulates type 2 cytokines.\n* Recent receipt of any marketed biologic drug or any investigational biologic for asthma or other diseases.\n* Recent live, attenuated vaccinations or planned live, attenuated vaccinations during the trial.\n* Participants that have been recently treated with bronchial thermoplasty.\n* Recent receipt of any investigational nonbiologic drug.\n* A recent chest X-ray or computed tomography with findings that are inconsistent for an asthmatic population.\n\nInclusion Criteria - COPD cohort\n\n* Body weight of ≥45 kg and BMI ≤45 kg\u002Fm2\n* Physician-diagnosed COPD\n* Must have experienced at least 1 COPD exacerbation requiring the use of systemic corticosteroids.\n* Participants in a stable condition must have a historical peripheral blood eosinophil count of ≥250 cells\u002FμL and\u002For FeNO ≥ 25 ppb.\n* Current or former smoker with a history of smoking of ≥10 pack-years.\n* Current acute COPD exacerbation requiring an urgent healthcare visit for treatment.\n* Peripheral blood eosinophil count of ≥300 cells\u002FμL as part of the assessment of the index acute COPD exacerbation.\n* Requires systemic corticosteroids as standard of care treatment in the urgent healthcare setting for the current acute COPD exacerbation.\n\nExclusion Criteria - COPD cohort\n\n* Regular use of immunosuppressive medication 12 weeks or 5 half-lives prior to approximately 12 weeks or 5 half-lives, whichever is longer.\n* Current diagnosis or a history of asthma, according to the Global Initiative for Asthma; or participants with a current diagnosis or history of Asthma COPD Overlap Syndrome.\n* Other respiratory disorders that might compromise the safety of the participant or affect the interpretation of the results.\n* Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension. Cardiac arrhythmias including paroxysmal atrial fibrillation.\n* Transient ischemic attack or stroke \\\u003C6 months from Screening Visit; hospitalization for any cardiovascular or cerebrovascular event \\\u003C6 months from Screening Visit.\n* Known or suspected history of immunosuppression.\n* History of known immunodeficiency disorder or hepatitis B or C.\n* History of alcohol abuse and\u002For drug abuse.\n* Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success.\n* Chronic treatment with long-term oxygen therapy or nocturnal oxygen therapy required for \\>15 hours a day.\n* Participants on long-term macrolide.\n* Current acute COPD exacerbation for which SoC was started \\>48 hours prior to Screening.\n* A recent chest X-ray or computed tomography scan reveals evidence of clinically significant abnormalities or pulmonary infection.\n* Female participant who is pregnant, lactating or breast-feeding.\n* Receipt of any marketed nonbiologic drug that modulates type 2 cytokines 30 days or 5 half-lives prior to SV1b, whichever is longer.\n* Receipt of any marketed or any investigational biologic for COPD or other diseases within 16 weeks or 5 half-lives, whichever is longer.\n* Live, attenuated vaccinations within 4 weeks prior to screening or planned live, attenuated vaccinations during the trial.\n\nThe above inclusion and exclusion criteria are not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","18 Years","85 Years",{"count":55,"type":21},40,[24],"A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation",[27,59],"COPD Exacerbation Acute",[61,30,62,63,64,65,66,67,68,69,70],"Acute exacerbation","Asthma exacerbation","CBP-201","Rademikibart","Connect Biopharma","COPD exacerbation","COPD acute","COPD","COPD flare","Asthma attack","2026-07-10",{"date":73,"type":36},"2026-07-15",{"date":75,"type":21},"2026-07-30",{"date":77,"type":21},"2027-01",{"name":79,"class":80},"Connect Biopharm LLC","INDUSTRY",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":101,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":44},"100642489","dash-obesity-explainable-ai-for-family-centric-personalized-weight-control-in-adolescents-and-young-adults-with-obesity-and-chronic-conditions-100642489","NCT07638345","DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions","US-based Clinical Sub-study of DASH-Obesity: Explainable AI for Family-Centric Transdiagnostic Personalized Weight Control Across Multiple Conditions","DASH-Obesity","Inclusion Criteria:\n\n* Adult caregiver (aged 18 years or older) of an adolescent or young adult aged 12 to 21 years diagnosed with Type 1 Diabetes (T1D) or asthma.\n* The caregiver is actively involved in the management of the adolescent's or young adult's condition.\n* The adolescent or young adult must meet one of the following criteria:\n* T1D and normal weight (BMI between the 10th and 85th percentile), or\n* T1D and overweight\u002Fobesity (BMI ≥85th percentile), or\n* Asthma and overweight\u002Fobesity (BMI ≥85th percentile).\n* Willingness to participate in the Adhera Caring Digital Program-Obesity (ACDP-O).\n* Access to a smartphone or internet-enabled device compatible with the study application.\n* Willingness to provide self-reported information regarding the adolescent's or young adult's health status, including disease-related and anthropometric measures.\n* For caregivers of participants with T1D, willingness to share continuous glucose monitoring (CGM) information.\n\nExclusion Criteria:\n\n* Severe psychiatric or cognitive conditions that would interfere with participation in the digital intervention.\n* Current participation in another obesity- or chronic disease-related digital health intervention study.\n* Inability or unwillingness to comply with study procedures.\n* Refusal or inability to provide informed consent.",true,{"count":91,"type":21},280,[93],"NA","This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with overweight\u002Fobesity and chronic conditions, including type 1 diabetes (T1D) and asthma. The intervention combines personalized educational content, wearable-device monitoring, psychometric assessments, and explainable artificial intelligence (AI) to improve mental well-being, quality of life, and adherence to healthy lifestyle behaviors. A total of 280 families will participate in a 3-month intervention with remote monitoring and follow-up assessments.",[96,97,98,99,27,100],"Type 1 Diabetes","T1D","Obesity & Overweight","Obesity Type 2 Diabetes Mellitus","Asthma (Diagnosis)",[102,96,30,103,104,105,106,107,108,109,110,111],"Pediatric Obesity","Overweight","Digital Health","Artificial Intelligence","Explainable AI","Caregiver Burden","Quality of Life","Mental Well-being","Wearable Devices","Family-Centered Care","RECRUITING","2026-06-19",{"date":115,"type":36},"2026-06-23",{"date":117,"type":36},"2025-10-30",{"date":119,"type":21},"2026-09",{"name":121,"class":80},"Adhera Health, Inc.",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":44},"100641326","post-exacerbation-asthma-clinic-telecare-intervention-to-reduce-recurrent-exacerbations-100641326","NCT07629830","Post Exacerbation Asthma Clinic Telecare Intervention to Reduce Recurrent Exacerbations","A Remote Clinic Intervention Following Hospital Discharge for Asthma Exacerbation to Reduce Recurrent Exacerbations","PACT","Inclusion Criteria:\n\n* Presentation to the emergency department with an asthma exacerbation.\n* Ability to complete telephone follow-up and access to a personal e-mail account.\n* Agreement to participate in the study.\n* Written or verbal informed consent according to study group assignment.\n\nExclusion Criteria:\n\n* Uncontrolled cardiac disease.\n* Any other uncontrolled medical condition.\n* Inability to complete telephone follow-up.\n* Pregnancy.\n* Patients lacking decision-making capacity.","75 Years",{"count":132,"type":21},220,[93],"Asthma exacerbations leading to emergency department visits or hospitalization are associated with a high risk of recurrent exacerbations, poor disease control, and increased healthcare utilization in the months following discharge. Early specialist follow-up during this vulnerable transition period remains limited, and many patients do not receive optimized long-term asthma management. The purpose of this study is to evaluate whether a structured remote asthma clinic intervention initiated shortly after hospital discharge can reduce recurrent exacerbations and improve asthma-related outcomes compared to standard community care.\n\nThis prospective randomized study will enroll 220 adult patients (18-75 years) presenting to the emergency department at Tel Aviv Sourasky Medical Center with an asthma exacerbation. Participants will be randomly assigned to one of two groups:\n\n1. Intervention group - will undergo two structured remote pulmonology follow-up visits via secure video consultation within 7-21 days and 5 months after discharge, including treatment optimization, inhaler technique assessment, and self-management education.\n2. Control group - will continue standard community care without additional intervention.\n\nAll participants will complete scheduled follow-up assessments over 12 months, including evaluation of exacerbations, asthma control, healthcare utilization, and medication use.",[27,136],"Asthma Attack",[138,139,140,141],"Asthma flare-up","Asthma management","remote clinic","pulmonologist","2026-06-18",{"date":144,"type":36},"2026-06-22",{"date":146,"type":21},"2026-07-01",{"date":148,"type":21},"2028-12-31",{"name":150,"class":151},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":89,"sex":16,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":44},"100626083","childrens-health-respiratory-inflammation-and-short-term-air-pollution-100626083","NCT07431021","Children's Health, Respiratory Inflammation and Short-term Air Pollution","CHERISH","Inclusion Criteria:\n\n* Attending schools in Central and East London that have been recruited to the study\n\nExclusion Criteria:\n\n* Not able to engage with PE lessons on safety grounds, reported by their parents.\n* Children with learning or physical disabilities sufficient for them to be unable to give informed assent to the study, or to carry out study procedures","7 Years","11 Years",{"count":162,"type":21},330,[93],"The goal of this study is to see if physical activity in high air pollution is worse than rest in high air pollution.",[27,166],"Respiratory",[168,169,170,171,172,173,174,175,176,177,178],"air pollution","physical activity","children","exercise","no2","Public health","air quality","pollution","paediatric","exposure","environment","2026-06-12",{"date":181,"type":36},"2026-06-15",{"date":183,"type":36},"2025-10-20",{"date":185,"type":21},"2027-07-01",{"name":187,"class":43},"Queen Mary University of London",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":89,"sex":16,"minAge":52,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":207,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":227},"100597211","creating-a-risk-assessment-tool-for-thunderstorm-asthma-the-carista-study-100597211","NCT07055542","Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study","Creating A RIsk Assessment Biomarker Tool to Prevent Seasonal and Thunderstorm Asthma: The CARISTA Study","CARISTA","Inclusion Criteria:\n\nConsenting adults aged 18 to 70 years with seasonal allergic rhinitis\n\nwilling to undertake:\n\n* Lung function testing\n* Blood sample collection for risk factor identification, -Prospectively logging their symptoms and medications through the springtime season using the CARISTA symptom monitoring platform . -\n\nExclusion Criteria:\n\n* Individuals unable to provide informed consent\n* Individuals who do not suffer from symptoms of seasonal allergic rhinitis\n* Individuals who do not consent to lung function testing and blood sample collection - Individuals with unstable asthma (FEV1 by spirometry less than 70% predicted), a recent exacerbation or change of asthma preventive medication use (within one month) would be excluded, although re-screening would be permitted after one month, time permitting.\n* Individuals with severe asthma requiring the use of continuous oral corticosteroids or biological medication for severe asthma.\n* The presence of any medical illness, such as cardiac disease, pre-existing illness or immunomodulatory therapy that, in the opinion of the Investigators, would compromise participant safety or the derivation of biomarkers during the study.","70 Years",{"count":198,"type":21},530,[93],"Thunderstorm asthma is a recurring public health emergency in South-Eastern Australia which occurs in springtime. The major identified risk factors for thunderstorm asthma is hay fever and allergy to ryegrass pollen. The goal of the CARISTA study is to identify the risk of springtime allergic and thunderstorm asthma in allergic adults living in South-Eastern Australia. To do this the investigators will recruit 530 people who have hay fever and test them for allergy to ryegrass pollen and undertake simple lung function testing. The investigators will ask study participants to complete a customised symptom tracker over the springtime pollen season for 2 consecutive years. The outcome the investigators are looking for is an asthma exacerbation or worsening asthma symptoms. This study will enable the investigators to identify indicators (biomarkers) of severe and moderate asthma exacerbations in order to identify those at risk of thunderstorm and seasonal asthma so protective treatments and strategies can be advised.",[202,203,204,205,206,27],"Allergic Asthma","Thunderstorm Asthma","Seasonal Allergic Rhinitis","Grass Pollen Allergy","Asthma Exacerbation Due to Thunderstorm",[208,209,210,211,212,213,214,215,216,217],"asthma","allergy","grass pollen allergy","ryegrass pollen","prospective symptom monitoring","seasonal allergic rhinitis","hay fever","seasonal allergic rhinoconjunctivitis","serum specific IgE","spirometry","2026-04-29",{"date":220,"type":36},"2026-05-06",{"date":222,"type":36},"2025-08-27",{"date":224,"type":21},"2030-12-31",{"name":226,"class":43},"University of Melbourne",6,{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":44},"100605778","phase-4-45th-multicenter-airway-research-collaboration-100605778","NCT07166939","45th Multicenter Airway Research Collaboration","A Phase 4, Multicenter, Cluster Randomized, Open-label, Intervention Versus Usual Care, Controlled Study on the Effect of Emergency Department Initiation of Airsupra on Asthma Outcomes","MARC-45","INCLUSION CRITERIA:\n\n* acute asthma\n* age 18.0 to 54.9 years\n* English and\u002For Spanish speaking\n* decision by ED attending to discharge patient to home on short course of systemic corticosteroids\n* (intervention group only) Willingness to use Airsupra as their rescue inhaler for next 3 months\n* demonstration of acceptable MDI administration technique\n* provision of informed consent prior to any study-specific procedures\n\nEXCLUSION CRITERIA:\n\n* involvement in the planning and\u002For conduct of the study\n* previous enrolment in the present study\n* prior diagnosis of COPD, chronic bronchitis, or emphysema\n* use of systemic corticosteroids in the past 2 weeks\n* participation in another clinical study with an investigational product during the past 4 weeks or the 3 months after enrollment in the current study\n* concurrent pneumonia\n* clinically significant cardiovascular disease or clinically significant cancer\n* patients with known hypersensitivity to Airsupra, albuterol sulfate, budesonide, or any of the excipients of the product\n* (for women only, by self-report):\n* currently pregnant\n* currently breastfeeding,\n* (among sexually active women of child-bearing age only) not using adequate contraception over the last 3 months, or no plan to use adequate contraception over the next 3 months\n* lack of a working cell phone and working email address\n* expected lack of availability for text and\u002For telephone follow-up at approximately 3, 6, and 12 weeks after the ED visit\n* inability to provide an alternate contact with a working cell phone and working email address.","54 Years",{"count":238,"type":21},1860,[240],"PHASE4","The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma \"recurrence\" at 3 months and other related outcomes (acute asthma relapse, asthma control).",[27,243,30,244],"Asthma Exacerbation","Asthma Control Level",[208,246,247,248,249,250,251,252,253],"emergency department","airsupra","randomized trial","acute asthma recurrence","acute asthma relapse","asthma control","acute asthma","asthma exacerbation","2026-04-14",{"date":256,"type":36},"2026-04-17",{"date":258,"type":36},"2025-11-07",{"date":260,"type":21},"2027-06",{"name":262,"class":43},"Massachusetts General Hospital",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":270,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":274,"phases":4,"briefSummary":268,"conditions":275,"keywords":279,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":290},"100624679","asmact-study-on-management-of-bronchial-asthma-100624679","NCT07412769","ASMact: Study on Management of Bronchial Asthma","Standardization According to GINA 2025 Recommendations for the Treatment, Management, and Follow-up of Acute Asthma Attacks: Observational, Multicenter Cohort Study.","Inclusion Criteria:\n\n* Age between 6 and 17 years\n* Presentation to the emergency department with a diagnosis of acute asthma exacerbation\n* Evaluation in the emergency department of one of the participating centers during the study periods\n\nExclusion Criteria:\n\n* Age \\\u003C 6 years or \\> 17 years\n* Diagnosis other than acute asthma exacerbation\n* Incomplete or missing clinical data\n* Patients transferred from other hospitals already treated for the same episode\n* history of allergy to any drugs used in the protocol","6 Years","17 Years",{"count":273,"type":21},500,"OBSERVATIONAL",[27,276,277,278],"Asthma Childhood","Asthma in Children","Asthma Crisis",[280],"asthma attack, exacerbation,","2026-02-13",{"date":283,"type":36},"2026-02-17",{"date":285,"type":36},"2025-11-05",{"date":287,"type":21},"2026-06-30",{"name":289,"class":43},"Meyer Children's Hospital IRCCS",2,{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":4},"100601589","phase-2-nebulized-ketamine-plus-standard-care-vs-standard-care-alone-in-moderate-to-severe-asthma-exacerbations-100601589","NCT07112456","Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations","Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations: A Randomized Clinical Trial (KET-AIR Trial)","KET-AIR","Inclusion Criteria:\n\n1. Adults aged 18 years or older presenting to the Emergency Department with a clinical diagnosis of moderate to severe asthma exacerbation based on SIGN (Scottish Intercollegiate Guidelines Network) criteria.\n2. PEFR between 33% and 75% of predicted value or personal best, as measured using a peak flow meter.\n3. Stable vital signs as deemed by the treating physician\n4. Alert and oriented, able to understand the study purpose and provide informed consent.\n5. Not requiring immediate advanced airway intervention, including intubation or emergency non-invasive ventilation.\n\nExclusion Criteria:\n\n1. Known hypersensitivity or allergy to ketamine or any component of the nebulized solution.\n2. History of psychosis, schizophrenia, or other severe uncontrolled psychiatric disorders.\n3. Uncontrolled hypertension, defined as systolic BP \\> 180 mmHg or diastolic BP \\> 110 mmHg on two consecutive readings at least 5 minutes apart, despite initial ED management.\n4. Hemodynamic instability, including persistent hypotension (SBP \\\u003C 90 mmHg) or tachyarrhythmias requiring urgent treatment.\n5. Significant chronic lung disease, including:\n\n   * COPD with frequent exacerbations or baseline FEV₁ \\\u003C 50% predicted\n   * Interstitial lung disease (ILD)\n   * Clinically significant bronchiectasis with baseline productive cough or infection\n6. Pregnancy or currently breastfeeding.\n7. Home BiPAP use or requirement for non-invasive ventilation (e.g., BiPAP\u002FCPAP) during the ED visit (Note: isolated home CPAP for sleep apnea without daytime symptoms is acceptable).\n8. Current intubation or imminent need for mechanical ventilation based on clinical judgment.\n9. Severe cardiac disease, including decompensated heart failure, recent myocardial infarction (\\\u003C6 weeks), or known severe valvular disease.\n10. Any other medical, surgical, or psychiatric condition that in the opinion of the investigator would place the patient at undue risk from study participation or interfere with the interpretation of study results.",{"count":300,"type":21},100,[24],"The goal of this clinical trial is to learn if nebulized ketamine helps treat moderate to severe asthma attacks in adults in the emergency department. It will also learn about the safety of ketamine when inhaled through a nebulizer.\n\nThe main questions it aims to answer are:\n\n* Does nebulized ketamine improve breathing more than standard treatment alone?\n* What side effects, if any, do participants experience after receiving nebulized ketamine?\n\nResearchers will compare nebulized ketamine to a placebo (a saltwater mist with no medication) to see how well it works and how safe it is.\n\nParticipants will:\n\n* Receive either nebulized ketamine or a placebo mist, along with standard asthma treatment\n* Have their breathing checked before and after treatment using a peak flow meter\n* Be monitored for 60 minutes and have their symptoms, vital signs, and any side effects recorded",[27,136,304],"Asthma Exacerbations",[30,306,243,307,31,308,309,310,311,312],"Asthma, Severe","Emergency Treatment","Ketamine, Nebulized","Bronchodilator Agents","Randomized Controlled Trial","Peak Expiratory Flow Rate","Safety and Efficacy","2025-08-01",{"date":315,"type":36},"2025-08-08",{"date":317,"type":21},"2026-09-01",{"date":319,"type":21},"2029-08-31",{"name":321,"class":151},"Oman Medical Speciality Board",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":44},"100545088","remote-patient-monitoring-solution-for-chronic-respiratory-disease-management-100545088","NCT06377345","Remote Patient Monitoring Solution for Chronic Respiratory Disease Management","Inclusion Criteria:\n\n* Diagnosis of asthma\n* Pediatric patients (age 7 to 17), adult patients (age 18 and above\n* Have an asthma exacerbation on the day of visit\n* Be willing to use the AeviceMD device\n* Has a smart phone to download the application that is paired with Aevice\n* Has wireless fidelity (WIFI) connection to use with Aevice\n* English speaking\n\nExclusion Criteria:\n\n* No capacity for consent\n* Concurrent chronic obstructive pulmonary disease (COPD)","90 Years",{"count":330,"type":21},180,[93],"Aim: To evaluate the use of AeviceMD Monitoring System (AeviceMD) asthma in reducing acute exacerbation.\n\nMethodology: Using a randomized controlled trial design, this project aims evaluate the effectiveness of AeviceMD in improving patients' outcomes in terms of reducing exacerbation, healthcare utilization, improving quality of life, self-efficacy, and cost effectiveness. Paediatric patients above age 7 and adults will be recruited. The data follow-up period is 3 months. It will also evaluate the usability of the device from both patients' and clinicians' perspective. 180 patients (124 adults, 56 pediatrics) and 120 clinicians will be recruited.\n\nImportance of study: This study will evaluate if the AeviceMD can help improve disease management and reduce recurrence of asthma exacerbation.\n\nPotential benefits and risk: AeviceMD allows for remote monitoring and tracking of patients' lung sounds, which could be used by patients to monitor their lung condition and prevent an episode of exacerbation or worsening exacerbations culminating in an admission which who further utilize already limited healthcare resources. An exacerbation is an episode of severe shortness of breath, cough, and chest tightening which warrants a visit to a healthcare institution. Through self-monitoring, patients can be empowered to self-manage their asthma, with aid of the asthma action plan which is given to all patients with asthma. AeviceMD can also help provide clinicians with patients' objective lung data. In the primary care setting, care is also fragmented as patients are often followed-up by a different doctor or healthcare providers. Clinicians have no objective data to track patients, and is dependent on patients' self-report and possible recall bias. There is no expected risk with the use of the device.",[30,136,277,27,334],"Asthma Chronic","2025-05-12",{"date":337,"type":36},"2025-05-15",{"date":339,"type":36},"2024-05-01",{"date":341,"type":21},"2025-12-30",{"name":343,"class":43},"SingHealth Polyclinics",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":89,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":22,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":44},"100517262","characterization-of-natural-killer-cells-in-severe-asthma-patients-in-comparison-with-control-subjects-100517262","NCT06015256","Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects","Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects: Identification of Biomarkers, Response During Virus-induced Exacerbations, and Interaction With Bronchial Epithelial Cells","NKAS","Inclusion Criteria:\n\nCases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers:\n\n* Consent form read, understood, approved and signed before any study procedure\n* Membership of a social security scheme or beneficiary of such a scheme\n* Patient aged over 18\n\nCases asthma controlled, uncontrolled excluding exacerbation, uncontrolled exacerbation:\n\n\\- Diagnosis of severe asthma confirmed by a respirologist at an expert centre\n\nCase asthma controlled:\n\n\\- Asthma control confirmed by a lung specialist from an expert centre\n\nCase uncontrolled asthma excluding exacerbation:\n\n\\- Uncontrolled asthma confirmed by a lung specialist from an expert centre\n\nCase uncontrolled asthma with exacerbation:\n\n\\- Current exacerbation\n\nExclusion Criteria:\n\nCases asthma controlled, uncontrolled excluding exacerbation, uncontrolled asthma exacerbation, and healthy volunteers:\n\n* Person subject to a legal protection measure\n* Vulnerable population: minors, persons under guardianship or trusteeship or persons deprived of their rights to liberty by court order.\n* women with a known pregnancy\n* Inability or refusal to comply with research requirements\n* Active or weaned smoker \\> 15 PA\n* Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or opioids in the 10 days prior to inclusion\n\nCase patient with asthma:\n\n\\- Coexistence of a chronic inflammatory disease other than asthma\n\nCase healthy volunteers:\n\n\\- Coexistence of an inflammatory pathology\n\nExclusion criteria:\n\nCases asthma: Pregnancy during follow-up Cases healthy volunteers: Total IgE level greater than 100 kU\u002FL (measured on the study sample)",{"count":353,"type":21},448,[93],"Asthma is a common chronic bronchial disease affecting 300 million people worldwide. The disease can be severe when it is not managed properly or when it is not controlled by treatments. Asthma is characterized by bronchial inflammation, bronchial hyperreactivity and tissue remodeling. Symptoms include episodes of coughing, dyspnoea and wheezing in relation with bronchial obstruction. The evolution is marked by the occurrence of exacerbations (increase of symptoms), most often triggered by viral infections, mostly due to rhinoviruses. The treatment of asthma is based on inhaled corticosteroid therapy sometimes combined with other treatments that help control the majority of asthma. However, about 10% of patients suffer from persistent symptoms despite these treatments.\n\nNatural killer (NK) cells are important actors of the antiviral innate immune response and are present in high numbers in the lungs. However, their role in severe asthma and its virus-induced exacerbations is unknown.\n\nThe purpose of this work is to characterize NK cells in severe asthma in order to identify molecules expressed differently from control subjects. The goal is to assess whether these molecules could be potential biomarkers of a severe asthma subtype, also known as the endotype, and\u002For be the molecular control for exacerbation. The advantage of identifying biomarkers for inflammatory diseases lies in their usefulness in establishing a correct diagnosis, monitoring the progress of the disease and the effectiveness of treatments. The secondary objectives are to characterize the activation of NK cells in response to in vitro rhinovirus infection of different types, in monoculture or in a model of interaction with a bronchial epithelium, and identify one or more molecules involved in the interaction between bronchial epithelial cells and NK cells.",[27],"2025-04-23",{"date":359,"type":36},"2025-04-25",{"date":361,"type":36},"2023-09-07",{"date":363,"type":21},"2030-09",{"name":365,"class":151},"Institut National de la Santé Et de la Recherche Médicale, France",{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":379,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":4},"100582915","study-on-acupuncture-treatment-of-chronic-airway-diseasesasthma-and-chronic-obstructive-pulmonary-disease-100582915","NCT06869525","Study on Acupuncture Treatment of Chronic Airway Diseases(Asthma and Chronic Obstructive Pulmonary Disease)","Study on the Efficacy and Mechanism of Acupuncture in the Acute Stage of Chronic Airway Diseases (Asthma and Chronic Obstructive Pulmonary Disease)","Inclusion Criteria:\n\n* Meets the diagnostic criteria for acute attack of asthma\u002FAECOPD;\n* Age range from18 years to 80 years(asthma) and 40 yesrs to 80 years(COPD);\n* The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form.\n\nExclusion Criteria:\n\n* Patients with combined pulmonary abscess, pulmonary interstitial fibrosis, active pulmonary tuberculosis, bronchiectasis and other pulmonary diseases;\n* Patients with severe cardiovascular and cerebrovascular diseases (such as malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, grade 3 or above cardiac function, stroke, cerebral hemorrhage, etc.);\n* Patients with severe liver diseases (such as liver cirrhosis, portal hypertension and bleeding caused by esophageal and gastric fundus varices) and severe kidney diseases (such as dialysis, kidney transplantation, etc.);\n* Patients with impaired consciousness or various mental disorders who are unable to communicate normally;\n* Pregnant and lactating women;\n* Those who are currently participating in other clinical trials within 1 month before enrollment;\n* Patients with contraindications to acupuncture (such as severe allergic or infectious skin diseases);","80 Years",{"count":375,"type":21},576,[93],"For patients in the acute phase of chronic airway diseases, on the basis of guideline-directed treatment, the experimental group was given acupuncture treatment, while the control group was given sham acupuncture treatment. The treatment lasted for one week, followed by a 13-week follow-up. For asthma and COPD, PEF and CAT were respectively used as the primary outcome measures to evaluate the clinical efficacy and safety of acupuncture. Based on the improvement of the primary outcome measures, the advantageous population was identified. The mechanism by which acupuncture reduces airway mucus hypersecretion was preliminarily explained.",[59,27],[59,27,380,310],"Acupuncture","2025-03-05",{"date":383,"type":36},"2025-03-11",{"date":385,"type":21},"2025-03",{"date":387,"type":21},"2027-12",{"name":389,"class":43},"Henan University of Traditional Chinese Medicine",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":16,"minAge":398,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":274,"phases":4,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":4},"100543770","retrospective-study-of-patients-with-acute-presentation-for-asthma-to-an-emergency-department-in-uk-rapae-100543770","NCT06360185","Retrospective Study of Patients with Acute Presentation for Asthma to an Emergency Department in UK (RAPAE)","Retrospective Study Investigating the Clinical Characteristic of Patients with Acute Presentation for Asthma to the A+E Department in a Busy Acute Hospital in England UK in Era of Biological Therapy for Asthma Between Jan 2019 & Jan 2024","RAPAE","Inclusion Criteria:\n\n* All Asthmatics patients who attend Emergency department over 5 years\n\nExclusion Criteria:\n\n* None Asthmatics.","16 Years","99 Years",{"count":401,"type":21},400,"Study team will obtain a list of all patients who have been seen in A+E over the past 6 years with a discharge diagnosis of asthma. Their history will be reviewed from their A+E notes. Team will obtain weight and height from Electronic prescribing tool and will obtain compliance information and past medical history from participant's GP records. Team will use participant's postcode to word out socio economic status quintile using office of national statistics tool. The following information will be taken from hospital documentation and from GP records.",[27],"2025-02-25",{"date":406,"type":36},"2025-02-27",{"date":408,"type":21},"2025-12",{"date":410,"type":21},"2027-12-01",{"name":412,"class":43},"Norfolk and Norwich University Hospitals NHS Foundation Trust"]